Diabetic Neuropathy Market by Treatment Type, Disorder Type, Distribution channel

Description

List of Tables

The Global Diabetic Neuropathy Market is forecasted to grow significantly, with a projected USD 3,504.36 million in 2023 at a CAGR of 6.35% and expected to reach a staggering USD 5,402.19 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Diabetic Neuropathy Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Diabetic Neuropathy Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Treatment Type, market is studied across Drugs and Physiotherapy. The Drugs is further studied across Analgesics, Anticonvulsants, and Antidepressant. The Analgesics is further studied across Non-Steroidal Anti-Inflammatory Drugs, Opioids, and Topical. The Anticonvulsants is further studied across Gabapentin, Pregabalin, and Topiramate. The Antidepressant is further studied across Serotonin & Norepinephrine Reuptake Inhibitors, SSRIs, and TCAs. The Drugs commanded largest market share of 46.12% in 2022, followed by Physiotherapy.

Based on Disorder Type, market is studied across Autonomic Neuropathy, Focal Neuropathy, Peripheral Neuropathy, and Proximal Neuropathy. The Peripheral Neuropathy commanded largest market share of 37.21% in 2022, followed by Autonomic Neuropathy.

Based on Distribution channel, market is studied across Clinics, Hospitals, Online Pharmacy, and Retail Pharmacy. The Hospitals commanded largest market share of 41.12% in 2022, followed by Retail Pharmacy.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 38.68% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Diabetic Neuropathy Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Diabetic Neuropathy Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Diabetic Neuropathy Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Diabetic Neuropathy Market?

4. What is the competitive strategic window for opportunities in the Global Diabetic Neuropathy Market?

5. What are the technology trends and regulatory frameworks in the Global Diabetic Neuropathy Market?

6. What is the market share of the leading vendors in the Global Diabetic Neuropathy Market?

7. What modes and strategic moves are considered suitable for entering the Global Diabetic Neuropathy Market?

Product Code: MRR-4348D129FA15

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Diabetic Neuropathy Market, by Treatment Type, 2022 vs 2030
4.3. Diabetic Neuropathy Market, by Disorder Type, 2022 vs 2030
4.4. Diabetic Neuropathy Market, by Distribution channel, 2022 vs 2030
4.5. Diabetic Neuropathy Market, by Region, 2022 vs 2030

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Rising prevalence of diabetic neuropathy and the need for effective treatment methods
  - 5.1.1.2. Increasing awareness pertaining to diagnosis & treatment of diabetes
  - 5.1.1.3. Government initiatives for the management of diabetic neuropathy
- 5.1.2. Restraints
  - 5.1.2.1. High failure rate in clinical trials and high cost of diabetic neuropathy treatment
- 5.1.3. Opportunities
  - 5.1.3.1. Widening diabetic neuropathy research areas
  - 5.1.3.2. Development of advanced drug delivery systems
- 5.1.4. Challenges
  - 5.1.4.1. Complications associated with diabetic neuropathy treatment
5.2. Market Trends
- 5.2.1. Ongoing research for the development of novel treatments and rise in approvals for diabetic neuropathy management systems in the Americas
- 5.2.2. Increasing prevalence of diabetes and emerging start-ups focused on developing diabetic neuropathy treatments and devices in the APAC region
- 5.2.3. Supportive government initiatives to improve diabetes disease treatment and care in the EMEA region
5.3. Cumulative Impact of COVID-19
5.4. Cumulative Impact of Russia-Ukraine Conflict
5.5. Cumulative Impact of High Inflation
5.6. Porter's Five Forces Analysis
- 5.6.1. Threat of New Entrants
- 5.6.2. Threat of Substitutes
- 5.6.3. Bargaining Power of Customers
- 5.6.4. Bargaining Power of Suppliers
- 5.6.5. Industry Rivalry
5.7. Value Chain & Critical Path Analysis
5.8. Regulatory Framework
5.9. Client Customization

6. Diabetic Neuropathy Market, by Treatment Type

6.1. Introduction
6.2. Drugs
- 6.2.1. Analgesics
  - 6.2.1.1. Non-Steroidal Anti-Inflammatory Drugs
  - 6.2.1.2. Opioids
  - 6.2.1.3. Topical
- 6.2.2. Anticonvulsants
  - 6.2.2.1. Gabapentin
  - 6.2.2.2. Pregabalin
  - 6.2.2.3. Topiramate
- 6.2.3. Antidepressant
  - 6.2.3.1. Serotonin & Norepinephrine Reuptake Inhibitors
  - 6.2.3.2. SSRIs
  - 6.2.3.3. TCAs
6.3. Physiotherapy

7. Diabetic Neuropathy Market, by Disorder Type

7.1. Introduction
7.2. Autonomic Neuropathy
7.3. Focal Neuropathy
7.4. Peripheral Neuropathy
7.5. Proximal Neuropathy

8. Diabetic Neuropathy Market, by Distribution channel

8.1. Introduction
8.2. Clinics
8.3. Hospitals
8.4. Online Pharmacy
8.5. Retail Pharmacy

9. Americas Diabetic Neuropathy Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Diabetic Neuropathy Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Diabetic Neuropathy Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
- 12.3.1. Merger & Acquisition
  - 12.3.1.1. Tandem Diabetes Care completed acquisition of insulin pump maker AMF Medical
  - 12.3.1.2. Withings acquired Devicemaker Impeto Medical
- 12.3.2. Agreement, Collaboration, & Partnership
  - 12.3.2.1. Praetego awarded USD 300,000 by National Eye Institute to advance novel oral drug for diabetic retinopathy
  - 12.3.2.2. P&G Health, IDF partnered to address Peripheral Neuropathy in people with diabetes
  - 12.3.2.3. The RMH partnered with Australian Centre for Accelerating Diabetes Innovations
- 12.3.3. New Product Launch & Enhancement
  - 12.3.3.1. Abbott, Medtronic, and Nevro are developing SCS therapies to treat peripheral neuropathy treatment

a diabetic for diabetic

12.3.3.2. NeuroMetrix launched peripheral neuropathy test DPNCheck 2.0
12.3.3.3. Glenmark Pharma launched drug for diabetic patients with comorbidities
12.3.3.4. FDA Clears PENS Device for pain related to diabetic peripheral neuropathy

12.3.4. Investment & Funding
- 12.3.4.1. Regenacy Pharmaceuticals announced the completion of enrollment for phase 2 Study in diabetic peripheral neuropathy & USD 9.3 million series B financing
- 12.3.4.2. Medtech startup Yostra Labs raised Rs 4Cr in a Seed round to help patients suffering from chronic disease
12.3.5. Award, Recognition, & Expansion
- 12.3.5.1. Horizon Therapeutics PLC announced FDA approval of an update to the indication language for TEPEZZA (teprotumumab-trbw) to specify its use in thyroid eye disease (TED) patients regardless of disease activity or duration
- 12.3.5.2. FDA cleared Medtronic's neurostimulator for diabetic peripheral neuropathy pain

13. List of Company Mentioned

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing